Detailed Information

Cited 12 time in webofscience Cited 15 time in scopus
Metadata Downloads

Management of entecavir-resistant chronic hepatitis B with adefovir-based combination therapiesopen access

Authors
Kim, Hyoung SuYim, Hyung JoonJang, Myoung KukPark, Ji WonSuh, Sang JunSeo, Yeon SeokKim, Ji HoonKim, Bo HyunPark, Sang JongLee, Sae HwanKim, Sang GyuneKim, Young SeokLee, Jung IlLee, Jin-WooKim, In HeeKim, Tae YeobKim, Jin-WookJeong, Sook-HyangJung, Young KulPark, HanaHwang, Seong Gyu
Issue Date
14-Oct-2015
Publisher
BAISHIDENG PUBLISHING GROUP INC
Keywords
Adefovir; Chronic hepatitis B; Entecavir; Lamivudine; Resistance
Citation
WORLD JOURNAL OF GASTROENTEROLOGY, v.21, no.38, pp.10874 - 10882
Indexed
SCIE
SCOPUS
Journal Title
WORLD JOURNAL OF GASTROENTEROLOGY
Volume
21
Number
38
Start Page
10874
End Page
10882
URI
https://scholarworks.korea.ac.kr/kumedicine/handle/2020.sw.kumedicine/7444
DOI
10.3748/wjg.v21.i38.10874
ISSN
1007-9327
Abstract
AIM: To evaluate the long-term efficacy adefovir (ADV)-based combination therapies in entecavir (ETV)-resistant chronic hepatitis B (CHB) patients. METHODS: Fifty CHB patients with genotypic resistance to ETV at 13 medical centers in South Korea were included for the analysis. All the patients received rescue therapy with the combination of ADV plus ETV (ADV/ETV, n = 23) or ADV plus lamivudine (LMV) (ADV/LMV, n = 27) for more than 12 mo. Patients were monitored at least every 3-4 mo during ADV-based combination therapy by clinical examination as well as biochemical and virological assessments. Hepatitis B virus (HBV) DNA levels were measured by real-time PCR and logarithmically transformed for analysis. Cumulative rates of virologic response (VR; HBV DNA < 20 IU/mL) were calculated using the Kaplan-Meier method, and the difference was determined by a log-rank test. Multivariate logistic regression and Cox proportional hazards models were used to identify independent risk factors significantly associated with short-term and long-term VR, respectively. RESULTS: Baseline median HBV DNA levels were 5.53 (2.81-7.63) log10 IU/mL. The most commonly observed ETV genotypic mutation sites were rt184 and rt202. Patients were treated for a median of 27 (12-45) mo. Overall, cumulative VR rates at 6, 12, 24, and 36 mo were 26%, 36%, 45%, and 68%, respectively. Patients treated with the ADV/ETV combination showed higher cumulative VR rates (35%, 43%, 65%, and 76%, respectively) than those with the ADV/LAM combination (18%, 30%, 30%, and 62%, respectively; P = 0.048). In the multivariate analysis, low baseline HBV DNA levels (< 5.2 log10 IU/mL) and initial virologic response at 3 mo (IVR-3; HBV DNA < 3.3 log10 IU/mL after 3 mo) were independent predictive factors for VR. Patients with favorable predictors achieved cumulative VR rates up to 90% at 36 mo. During the same period, the cumulative incidence of virologic breakthrough was as low as 6% in patients with the both favorable predictors. CONCLUSION: If tenofovir is not available, ADV/ETV combination could be considered in ETV-resistant patients with low HBV DNA titers, and may be continued if IVR-3 is achieved.
Files in This Item
There are no files associated with this item.
Appears in
Collections
2. Clinical Science > Department of Gastroenterology and Hepatology > 1. Journal Articles

qrcode

Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.

Related Researcher

Researcher Jung, Young Kul photo

Jung, Young Kul
Ansan Hospital (Department of Gastroenterology and Hepatology, Ansan Hospital)
Read more

Altmetrics

Total Views & Downloads

BROWSE